🇺🇸 FDA
Pipeline program

MIDAZOLAM , CEDACONDA 100 % V/V, liquide pour inhalation par vapeur, PROPOFOL

APHP230844

Phase 3 small_molecule active

Quick answer

MIDAZOLAM , CEDACONDA 100 % V/V, liquide pour inhalation par vapeur, PROPOFOL for Adult patients with severe cardiogenic shock on venoarterial ECMO support for less than 24 hours. is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Adult patients with severe cardiogenic shock on venoarterial ECMO support for less than 24 hours.
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials